Siegfried Shareholders Back Capital Reduction and New Board Leadership at AGM

Siegfried Holding AG ( (CH:SFZN) ) has provided an update.

Siegfried Holding AG, a global life sciences and pharmaceutical manufacturing specialist listed on SIX Swiss Exchange, reported 2025 sales of CHF 1,327.8 million and more than 3,800 employees across 13 sites in Europe, the U.S. and China. The group focuses on producing APIs, intermediates and a range of drug products while also offering development services to pharmaceutical customers.

At its 123rd Annual General Meeting in Zofingen, Siegfried shareholders approved all Board proposals, including the 2025 financial statements and a reduction of the ordinary share capital via a nominal value cut of CHF 0.40 per share to CHF 0.32, with payment scheduled for late April 2026. Investors also backed an extension of the capital band for potential share capital increases, granted discharge to the Board, approved executive and Board remuneration, and endorsed a refreshed board leadership with Beat Walti elected Chair and industry experts Karl Petersson and Thomas Wozniewski joining the Board, reinforcing governance continuity and strategic expertise.

The most recent analyst rating on (CH:SFZN) stock is a Hold with a CHF85.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.

More about Siegfried Holding AG

The Siegfried Group is a global life sciences company that manufactures pharmaceutical active ingredients, intermediates and finished dosage forms such as tablets, capsules and sterile injectables for the pharmaceutical industry. Headquartered in Zofingen and listed on SIX Swiss Exchange, it operates 13 sites across Europe, the U.S. and China, generated CHF 1.33 billion in sales in 2025, and employs more than 3,800 people worldwide.

Average Trading Volume: 123,232

Technical Sentiment Signal: Buy

Current Market Cap: CHF3.76B

See more data about SFZN stock on TipRanks’ Stock Analysis page.